The U.S. drug industry will unveil today its Code on Interactions with Health Care Professionals, a voluntary guideline aimed at encouraging companies to stop giving gifts and to limit payments to providers. The modified code -- formulated by the Pharmaceutical Research and Manufacturers of America -- calls for firms to set an annual cap on fees for speaking and consulting deals with providers. The revised rules do not apply to biotech or medical-device makers.

Related Summaries